ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...

Toxicity was moderate: febrile neutropenia, grade 3 infection, grade 2 neurotoxicity, and decreased LVEF after 23 cycles of trastuzumab were observed in 1 patient each. Conclusion: HER2 ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy.

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in ...

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

The FDA has granted priority review to the new drug application for zongertinib to treat adults with unresectable or metastatic, HER2-mutant NSCLC who have received prior systemic therapy.

The US company also sells a small-molecule HER2 inhibitor – Tukysa (tucatinib ... the scale well below the $6.9 billion bundle – including $1.3 billion upfront A- that Z laid down for ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung cancer (NSCLC), typically in female individuals, who are non-smokers, and have ...